Short answer
ResMed (RMD) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 4.01 (Changes in Registrant's Certifying Accountant), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). KPMG dismissed August 13, 2026 after auditing fiscal years ended June 30, 2026 and 2025.
- This filing includes Item 4.01, an item that often signal trouble.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 4.01 · Changes in Registrant's Certifying Accountant
- KPMG dismissed August 13, 2026 after auditing fiscal years ended June 30, 2026 and 2025
- Clean transition record: no qualified opinions, accounting disagreements, or reportable events disclosed
- Audit Committee selected PwC for fiscal year ending June 30, 2027 following a competitive review
- PwC had no prior consultations with ResMed on accounting, auditing, or financial reporting issues
- KPMG’s response letter filed as Exhibit 16.1, supporting the disclosed transition terms
Item 5.02 · Departure/Election of Directors or Officers
- Ronald Taylor retiring from ResMed’s Board at the expected November 18, 2026 annual meeting
- Departure unrelated to disagreements over operations, policies, or practices
- Carol Burt appointed lead director effective November 15, 2026
- Leadership transition preserves board oversight before Taylor’s departure
Item 7.01 · Regulation FD Disclosure
- Taylor’s retirement effective at the Annual Meeting creates a board leadership transition
- Burt appointed lead director effective November 15, 2026, indicating planned governance succession
- Press release furnished as Exhibit 99.1 with additional transition details
Item EX-99.1 · Exhibit EX-99.1
- Carol Burt becomes Lead Director on November 15, 2026, succeeding Ron Taylor
- Taylor will retire after more than 21 years on Resmed’s Board and will not seek reelection at the November 18 annual meeting
- Burt’s appointment provides leadership continuity, with Board service since 2013 and current governance committee chairmanship
- Leadership transition affects governance oversight, not Resmed’s executive management or stated long-term strategy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.